正川股份(603976) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 161,572,393.90, a decrease of 34.24% compared to CNY 245,711,123.16 in the same period last year[3] - Net profit attributable to shareholders was CNY 10,914,129.26, down 48.15% from CNY 21,047,590.27 year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 9,034,224.24, reflecting a decline of 55.68% compared to CNY 20,382,258.79 in the previous year[3] - Basic and diluted earnings per share were both CNY 0.07, a reduction of 50.00% from CNY 0.14 in the same period last year[3] - Total operating revenue for Q1 2025 was ¥161,572,393.90, a decrease of 34.2% compared to ¥245,711,123.16 in Q1 2024[14] - Net profit for Q1 2025 was ¥10,914,129.26, a decline of 48.0% compared to ¥21,047,590.27 in Q1 2024[15] - Basic and diluted earnings per share for Q1 2025 were both ¥0.07, down from ¥0.14 in Q1 2024[16] - Other income for Q1 2025 was ¥2,640,103.11, down from ¥6,429,327.42 in Q1 2024[14] Cash Flow and Assets - The net cash flow from operating activities increased by 313.93%, reaching CNY 19,115,298.02, primarily due to a decrease in cash paid for goods and services[3] - Cash flow from operating activities for Q1 2025 was ¥19,115,298.02, an increase from ¥4,617,978.95 in Q1 2024[18] - Cash and cash equivalents increased to RMB 130,566,143.60 from RMB 108,902,577.00, representing a growth of about 20%[11] - Cash and cash equivalents at the end of Q1 2025 totaled ¥92,816,312.12, compared to ¥177,123,351.40 at the end of Q1 2024[19] - The company's current assets totaled RMB 897,684,693.14, compared to RMB 875,859,570.37 at the end of 2024, reflecting a growth of approximately 2.9%[12] - Accounts receivable rose to RMB 161,678,291.09 from RMB 148,208,950.23, indicating an increase of approximately 9%[11] - Inventory levels increased to RMB 264,459,834.96 from RMB 250,483,335.27, marking a growth of around 5.6%[12] - Total assets at the end of the reporting period were CNY 1,963,698,882.49, a slight increase of 0.35% from CNY 1,956,811,650.01 at the end of the previous year[6] - As of March 31, 2025, the company's total assets amounted to RMB 1,963,698,882.49, an increase from RMB 1,956,811,650.01 as of December 31, 2024[12] Liabilities and Equity - The total liabilities decreased slightly to RMB 729,377,826.55 from RMB 733,404,723.33, a reduction of about 0.4%[13] - The company's equity attributable to shareholders increased to RMB 1,234,321,055.94 from RMB 1,223,406,926.68, reflecting a growth of approximately 0.8%[13] - Shareholders' equity attributable to the parent company was CNY 1,234,321,055.94, up 0.89% from CNY 1,223,406,926.68 at the end of the previous year[6] - The company reported a decrease in short-term borrowings, contributing to a more favorable liquidity position[13] Market and Competition - The decline in revenue and profit was attributed to intensified competition in the pharmaceutical market, changes in medical insurance payment policies, and fluctuations in downstream customer demand[7] - The company is focusing on expanding its market presence and enhancing product development strategies[11] Non-Recurring Items and Accounting Changes - Non-recurring gains and losses included government subsidies of CNY 1,496,511.02, which positively impacted the financial results[5] - The company reported a decrease in research and development expenses to ¥3,597,362.58 in Q1 2025 from ¥6,614,118.01 in Q1 2024, a reduction of 45.4%[14] - The company will implement new accounting standards starting from 2025, which will involve adjustments to the financial statements at the beginning of the year[20]